Pricing

Michel Bouvier

Chairman, Scientific Advisory Board at Domain Therapeutics SA

Michel Bouvier

Michel Bouvier

Chairman, Scientific Advisory Board at Domain Therapeutics SA

Overview

RelSci Relationships

45

Number of Boards

2

Relationships

View Relationship Details

RelSci Relationships are individuals Michel Bouvier likely has professional access to. A relationship does not necessarily indicate a personal connection.

Barry Byrne

Founder at Applied Genetic Technologies Corp.

Relationship likelihood: Strong

Stuart Kornfeld

Professor, Department of Biochemistry & Molecular Biophysics at Washington University in St.Louis - School of Medicine

Relationship likelihood: Strong

Pascal Neuville

Chief Executive Officer, Director & Chief Scientific Officer at Domain Therapeutics SA

Relationship likelihood: Strong

John F. Crowley

Chairman of the Board, Chief Executive Officer at Amicus Therapeutics, Inc.

Relationship likelihood: Strong

Bradley Lewis Campbell

President, Chief Operating Officer & Director at Amicus Therapeutics, Inc.

Relationship likelihood: Strong

Pierre Potier

Founder at Domain Therapeutics SA

Relationship likelihood: Average

Yves Dunant

Founder at Domain Therapeutics SA

Relationship likelihood: Average

Maurice Israel

Founder at Domain Therapeutics SA

Relationship likelihood: Average

Youssef L. Bennani

Vice President-Research & Development at Vertex Pharmaceuticals

Relationship likelihood: Average

Florian Denis

Associate at Auriga Partners SA

Relationship likelihood: Average

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.

In The News

ENP Newswire

December 5, 2018

-Domain Therapeutics signs a multi-target research collaboration and license agreement with Boehringer Ingelheim on G Protein-Coupled Receptors

FierceBiotech

December 4, 2018

Boehringer inks pact with Domain for GPCR neurology drugs

ENP Newswire

February 28, 2018

-Domain Therapeutics grants Bristol-Myers Squibb non-exclusive license for G protein-coupled receptor bioSens-All technology

PR Newswire

June 15, 2015

New company will benefit patients undergoing transplants for leukemias

peHUB

April 8, 2015

AmorChem invests in cancer immunotherapy R&D program

Paths to Michel Bouvier

Potential Connections via
Relationship Science

You

Michel Bouvier

Chairman, Scientific Advisory Board at Domain Therapeutics SA

Boards & Committees

Chairman, Scientific Advisory Board

2014 - Current

Domain Therapeutics SA

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm's products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Israël, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in October 2001 and is headquartered in Illkirch-Graffenstaden, France.

Member, Scientific Advisory Board

Tenure Unconfirmed

Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc. is a biotechnology company, which is engaged in the discovery, development and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Creating a news feed is your most valuable research tool. RelSci sends you actionable updates so you can keep tabs on the people and organizations you care about most.

Browse in-depth profiles on 10 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Creating a news feed is your most valuable research tool. RelSci sends you actionable updates so you can keep tabs on the people and organizations you care about most.

Browse in-depth profiles on 10 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Michel Bouvier. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Michel Bouvier's profile does not indicate a business or promotional relationship of any kind between RelSci and Michel Bouvier.

Most Connected Accounting and Financial Services Executives How to Make a Good Impression on Venture Capitalists - Relationship Science Business Leaders Share the Best Networking Tips They've Ever Receiv...